Last reviewed · How we verify
non-renin angiotensin system blockers
At a glance
| Generic name | non-renin angiotensin system blockers |
|---|---|
| Also known as | norvasc, adalat retard, betaloc, natrilix or aldomet |
| Sponsor | Hospital Authority, Hong Kong |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The COVID-RASi Trial (COVID-19) (PHASE3)
- Long-term Use of CCB and Breast Cancer Risk
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Registry Of Best Up-titration STrategies in Acute Heart Failure
- Study of Preoperative Management of Angiotensin Converting Enzyme Inhibitor (ACEi) and Angiotensin Receptor Blocker (ARB) Medications (NA)
- Asian Diabetes Outcomes Prevention Trial (PHASE4)
- Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: